

## 1 SUPPLEMENTAL METHODS

2

3 A graphical version of our methods can be found in **Figure S9**.

4

### 5 ***BMI Stratification***

6 We stratified our cohort into three categories of BMI: High, Mid, and Low. In order to determine which  
7 individuals fell into each group, we looked at the distribution of BMI for each ancestry group and sex  
8 (**Figures S1 and S2**). Within each distribution, we decided to use the quartiles of the normal distribution  
9 as our cut-offs for assigning BMI group (**Figure S1**). Individuals whose BMI fell above the 3<sup>rd</sup> quartile of  
10 the BMI distribution were assigned to the High BMI category, those who fell below the 1<sup>st</sup> quartile were  
11 assigned to Low BMI, and those whose BMI fell between the 1<sup>st</sup> and 3<sup>rd</sup> quartile of the distribution were  
12 assigned to the Mid BMI group. **Tables S2 and S3** describe the BMI values for each ancestry and sex, as  
13 well as the range of BMI values included in each group for each ancestry and sex.

14

### 15 ***BioMe BRSPD File QC***

16 All of the BioMe-R Structured Phenotype Database (BRSPD) files underwent a fairly extensive QC  
17 process to correct misspelled variable fields, remove extraneous symbols, standardize units of measure,  
18 and replace spaces with underscores (“\_”). All of the files were originally delimited by the “|” symbol, and  
19 thus were converted to a tab-delimited format for pheWAS use. Many files had variable fields with  
20 variations on the same phenotype or measure (for example 1mg/mL could be written as “1\_mg/mL”,  
21 “1mg/mL”, “1mg1mL”, “1mg/1mL”, etc.). These measures and phenotypes needed to be collapsed and  
22 standardized before input into pheWAS. Likewise, there were a few phenotypes, specifically the vital sign  
23 measurements, where each individual had many measurements, with each measurement representing an  
24 encounter with the healthcare system. In order to look at the overall association with these phenotypes,  
25 continuous vital sign measures with multiple entries were collapsed into four measures: highest measure  
26 recorded, lowest measure recorded, mean measure, and variance of measure.

27

28 *Allergies*

29 Known allergies and notes on allergic reaction were entered in the original Allergy file, which included  
30 individual ID, allergen, date of entry, and notes on the allergic reaction (if available). Most QC of the  
31 allergy file entailed collapsing variables of the same or similar phenotype. For example, allergy to tree  
32 nuts could be noted as “TREE NUT”, “TREE NUTS”, “TREE NUT UNSPECIFIED”, and “NUT, TREE”. All  
33 of these phenotypes were collapsed into the category of “TREE NUT”. After QC of the Allergy file and  
34 application of selection criteria for sample size and phenotype counts, we had a total of 113 Allergy  
35 phenotypes available for pheWAS. These phenotypes are listed in **Table S12**.

36

### 37 *Encounter Diagnosis*

38 The encounter diagnosis file comprises the primary diagnoses, denoted by the International Classification  
39 of Disease (ICD) 9 and 10 codes, assigned to each patient by the clinician in their visits and interactions  
40 with the health system. Most diagnosis codes in the encounter diagnosis file are ICD-10 codes, however,  
41 there were a few diagnoses that were still using ICD-9 codes that had not been converted. We converted  
42 the original encounter diagnosis file, which consisted of information on patient ID, diagnosis code, date of  
43 entry, notes, and code description, into counts of each diagnosis code per individual. The PheWAS R  
44 package *createPhewasTable* function uses this count information to select cases of a particular diagnosis  
45 to have a count of 2 or more diagnosis codes, select controls with counts of 0 and exclude individuals  
46 with only 1 count of a particular code. After QC, we had a total of 2,178 phenotypes available for pheWAS  
47 (**Table S7**).

48

### 49 *Encounter Orders*

50 The encounter orders file describes the various lab tests and other procedures ordered by the clinician  
51 upon the individual's encounter with the healthcare system. Similar to the encounter diagnosis file, the  
52 encounter orders file includes individual ID, the encounter order procedure code, date of encounter, any  
53 notes from the clinician, and notes on whether the order was complete or currently being carried out. For  
54 this phenotype, each individual was noted as “TRUE” or “FALSE” as to whether they were assigned a  
55 particular order. After QC, there were a total of 1,609 phenotypes available for pheWAS (**Table S13**).  
56 Descriptions of the procedure codes were available in the original encounter orders file.

57

58 *Family History*

59 Family history of disease phenotypes were noted with the relation with the disorders such as mother,  
60 father, sister, brother, paternal grandmother, maternal grandmother, etc. We collapsed each phenotype  
61 based on the relationship degree in order to reduce the number of tests. Relationships of mother, father,  
62 sister, brother, son, daughter, and child were categorized as “first degree”. Grandchild, half-brother, half-  
63 sister, maternal aunt, maternal grandfather, maternal grandmother, maternal uncle, paternal aunt,  
64 paternal grandfather, paternal grandmother, and paternal uncle were categorized as “second degree”.  
65 Cousin, maternal great aunt, maternal great grandfather, maternal great grandmother, maternal great  
66 uncle, paternal great aunt, paternal great grandfather, paternal great grandmother, and paternal great  
67 uncle were categorized as “third degree”. Foster, spouse, stepbrother, stepfather and stepsister were  
68 categorized as “no relation”. After QC, there were a total of 144 phenotypes for pheWAS. All available  
69 phenotypes are listed in **Table S14**.

70

71 *Medications*

72 We used CLAMP, a clinical natural language processing algorithm, to identify the core ingredients of  
73 unique BioMe™ prescriptions from the EHR-derived medications file. Using the unstructured BioMe™  
74 prescriptions as input, CLAMP returns an RxNorm concept unique identifier (RXCU) for any prescription  
75 that contains a suspected drug name. After manual review of 100 random RXCUIs output by CLAMP,  
76 each RXCU from CLAMP was then reintroduced to the RxNorm API to standardize the drugs by their  
77 ingredients. From this we were able to collapse and standardize medication names for PheWAS based  
78 on their common drug name. For example, sertraline, the generic name for the brand-name SSRI Zoloft,  
79 would encompass prescriptions for both the generic name “sertraline” as well as “Zoloft”. After QC a total  
80 of 951 medication phenotypes were available for pheWAS (**Table S11**).

81

82 *Personal History*

83 Personal history phenotypes were extracted from a large 156-question questionnaire that had information  
84 on demographics, social history, education, behavior, personal medical history, and more. After QC, a  
85 total of 35 phenotypes were available for pheWAS. **Table S15** lists all phenotypes available for analysis.

86

#### 87 *Social History (Alcohol, Illicit Drug and Tobacco use; Sexual History)*

88 Social history variables containing information on education, tobacco and alcohol use, illicit drug use, and  
89 sexual history were available within the BRSPD files. We split this file into multiple phenotype files  
90 encompassing categorical and continuous measures of tobacco, alcohol and illicit drug use, as well as  
91 sexual history. Continuous measures of alcohol use were measured as ounces of alcohol consumed per  
92 week, illicit drug use was measured as frequency or number of times used, and tobacco use was  
93 separated into two continuous measures of number of cigarette packs smoked per day and number of  
94 years of tobacco use. Categorical measures of alcohol, illicit drug and tobacco use included Y/N  
95 questions on use and exposure (yes/no) and type of user (current, past, never), as well as type of  
96 tobacco (cigarettes, cigars, pipes or chew). Sexual history consisted of categorical measures of sexual  
97 activity and contraceptive use. Phenotypes available for social history are described in **Table S9**.

98 Distributions of continuous phenotypes are shown in **Figure S10**.

99

#### 100 *OBGYN History*

101 Obstetric history was derived from a file that included individual, type of pregnancy and/or parity (term,  
102 preterm, ectopic, abortion, therapeutic abortion, spontaneous abortion, para, and gravida), and date of  
103 OBGYN encounter. We took the OBGYN file and created two phenotype types for our pheWAS: (1)  
104 categorical Y/N for presence of a certain OBGYN outcome (2) continuous counts of the OBGYN outcome  
105 (**Figure S11**). **Table S16** describes OBGYN phenotypes available.

106

#### 107 *Vital Signs (Height, Weight, Blood Pressure, Temperature, Respirations, Pulse, Pulse Oximetry, Pain 108 Score, and Pain Location)*

109 The original vital signs file included information on Individual ID, type of vital sign, vital sign measure, unit  
110 of measure, and date of measurement for nine signs: blood pressure, height, pain score and location,  
111 pulse, pulse oximetry, respirations, temperature, and weight. Multiple measures were made for each

112 individual's encounter with the Mount Sinai health system. To account for these multiple measures we  
113 first removed any measurements that were clear, biologically impossible outliers (e.g. an individual who  
114 had a height measurement of 1,200 inches), then standardized all measurements to the same unit (e.g.  
115 cm for height, kg for weight and degrees Celsius for temperature), and finally summarized each  
116 individual's measurements into four measures per phenotype: highest recorded measurement, lowest  
117 recorded measurement, mean measurement and variance. Blood pressure measurements were given as  
118 separate systolic and diastolic pressure measurements, and we also included a measure of pulse  
119 pressure, which was calculated as the difference between systolic and diastolic measurements. **Table S6**  
120 and **Figure S12** describe vital sign phenotypes available and their distributions.

121  
122 For the weight phenotype, we chose to use three measurements: highest recorded weight, lowest  
123 recorded weight, and weight change over time, which was calculated by using the earliest and most  
124 recent recorded weight measures divided by the number of years between those records as the average  
125 number of kg change per year. This obviously will not reflect weight cycling and other trajectories over  
126 time, but gives us a rough mean estimate of weight fluctuation over time. Future analyses will include  
127 more precise weight trajectories for our pheWAS. Distribution of weight phenotypes is shown in **Figure**  
128 **S13**.

129  
130 For pain score and location, we created measurements that we hoped captured both the severity of pain  
131 recorded (pain score is a 0 to 10 scale, with 0 as no pain and 10 being the most severe pain ever  
132 experienced), as well as the number of times an individual reported a particular pain score. We created  
133 pain score measurements that included highest recorded (with a maximum value of 10), mean pain score,  
134 and pain score sum, which was the sum of all recorded pain score measurements. In addition to pain  
135 score, we also had pain location recorded with pain score. We further created pain score by location,  
136 where each location was assessed for highest, mean, and sum pain scores. We looked at pain location  
137 overall, regardless of score, as an additional phenotype. **Table S10** and **Figure S14** describe pain score  
138 phenotypes available and their distributions.

139  
140

## 141 SUPPLEMENTAL RESULTS

### 142 ***S-PrediXcan of AN***

143 We used a binomial test to look for tissue enrichment within our experiment-wide significant gene-tissue  
144 associations and found no significant enrichment of any tissue. We then looked at tissue enrichment  
145 across nominally significant gene-tissue associations ( $p < 0.05$ ) and found significant enrichment of whole  
146 blood tissue ( $p = 5.77 \times 10^{-7}$ , proportion of tests = 0.0232, proportion of hits = 0.0290), as well as significant  
147 under-enrichment in CMC DLPFC ( $p < 2.20 \times 10^{-16}$ , proportion of tests = 0.0398, proportion of hits = 0.0171)  
148 and GTEx Testis tissues ( $p = 0.02994$ , proportion of tests = 0.0335, proportion of hits = 0.0306).

149

### 150 ***AN-GReX PheWAS***

151 Full summary statistics from our AN-GReX PheWAS for all phenotypes can be found in **Table S17**.

152

### 153 ***Allergies***

154 After QC, a total of 179 allergy phenotypes were tested for association with AN-GReX. In the overall  
155 BioMe™ cohort, downregulation of *PFKFB4* was associated with allergy to both the antibiotic tetracycline  
156 (Skin Not Sun Exposed-*PFKFB4*,  $p = 4.12 \times 10^{-6}$ ) and gut motility drug metoclopramide (Brain cortex-  
157 *PFKFB4*,  $p = 9.49 \times 10^{-6}$ ). Similarly, in individuals with Mid and Low BMI, downregulation of *PFKFB4* was  
158 associated with allergy to tetracycline (Mid-Skin Not Sun Exposed-*PFKFB4*,  $p = 1.13 \times 10^{-5}$ ; Mid-Skin Sun  
159 Exposed-*PFKFB4*,  $p = 2.90 \times 10^{-4}$ ; Low-Skin Not Sun Exposed-*PFKFB4*,  $p = 4.51 \times 10^{-4}$ ). Downregulation of  
160 *PFKFB4* in individuals with Mid BMI was also associated with allergy to the diabetic drug metformin (Mid-  
161 Lung-*PFKFB4*,  $p = 1.44 \times 10^{-4}$ ) and upregulation to the analgesic acetaminophen (Mid-Esophagus  
162 Mucose-*PFKFB4*,  $p = 9.28 \times 10^{-6}$ ). Additionally, downregulation of *PFKFB4* was associated with allergy to  
163 the antibiotic vancomycin in High BMI individuals (High-Brain Cortex-*PFKFB4*,  $p = 9.89 \times 10^{-5}$ ; High-Cells  
164 Transformed lymphocytes-*PFKFB4*,  $p = 3.37 \times 10^{-4}$ ). Upregulation of *SLC2A10* was associated with allergy  
165 to morphine in the overall cohort (Colon transverse-*SLC2A10*,  $p = 1.85 \times 10^{-5}$ ; Esophagus Mucosa-  
166 *SLC2A10*,  $p = 8.10 \times 10^{-5}$ ). Additional allergy associations are provided in **Table S12**.

167

168 **Encounter Orders**

169 Encounter orders are coded orders from the EHR for various laboratory tests and procedures, dietary  
170 restrictions and other medication orders. After QC, there were a total of 2,147 unique encounter order  
171 codes tested for association with AN-GReX. Full summary statistics for encounter orders are provided in  
172 **Table S13**.

173

174 In the overall cohort, downregulation of *ARIH2*, *NCKIPSD* and *DALRD3*, and upregulation of *CCDC71*,  
175 *SPINK8* and *WDR6* were associated with encounter order “DIET24”, an order for a regular diet (Heart Left  
176 Ventricle-*ARIH2*,  $p=8.95 \times 10^{-6}$ ; Multiple tissues-*NCKIPSD*,  $p<2.21 \times 10^{-5}$ ; Cells Transformed  
177 Lymphocytes-*DALRD3*,  $p=8.33 \times 10^{-6}$ ; Brain Frontal Cortex-*CCDC71*,  $p=1.75 \times 10^{-5}$ ; Brain Hippocampus-  
178 *SPINK8*,  $p=1.21 \times 10^{-5}$ ; Brain Frontal Cortex-*WDR6*,  $p=1.02 \times 10^{-5}$ ; Brain Putamen basal ganglia-*WDR6*,  
179  $p=7.59 \times 10^{-6}$ ; Brain Substantia Nigra-*WDR6*,  $p=3.79 \times 10^{-6}$ ). *ARIH2*, *CCDC71* and *WDR6* were  
180 additionally associated with encounter order “OPH1122”, coded for “Ophthalmoscopy subsequent  
181 performed”, along with upregulation of *CCDC36* (Upregulation-Heart Left Ventricle-*ARIH2*,  $p=2.17 \times 10^{-5}$ ;  
182 Upregulation-Multiple tissues-*CCDC36*,  $p<1.95 \times 10^{-5}$ ; Downregulation-Multiple tissues-*CCDC71*,  $p<2.09$   
183  $\times 10^{-5}$ ; Downregulation-Brain Putamen basal ganglia-*WDR6*,  $p=1.84 \times 10^{-5}$ ). Additional encounter orders  
184 associated with AN-GReX in the overall cohort include order “51701” for insertion of a bladder catheter,  
185 “97112” for Neuromuscular re-education, “96372” for therapeutic, prophylactic and diagnostic injections  
186 and infusions, “100696” for a pregnancy-induced hypertension panel, “102915” for IFE interpretation,  
187 “600536” for pelvic ultrasound and “NUR577” for calorie count (**Table S13**).

188

189 Downregulation of *ARIH2*, *CCDC36*, and *DALRD3* and upregulation of *CCDC71* and *WDR6* (all of which  
190 were all associated with “DIET24” in the overall cohort), were associated with encounter order “PRE5” for  
191 fall precautions in individuals with Low BMI ( $p<3.85 \times 10^{-5}$ ; **Table S13**). Additional associations within  
192 individuals of Low BMI were downregulation of *SLC26A10* with order “100478” for surveillance of multi-  
193 drug-resistant gram-negative bacterial respiratory infection (Low-Liver-*SLC26A10*,  $p=1.70 \times 10^{-5}$ ),  
194 downregulation of *FBLIM1* with code “600536” for non-obstetric pelvic ultrasound (Low-DLPFC-*FBLIM1*,  
195  $p=3.49 \times 10^{-5}$ ), and downregulation of *DALRD3* with “DIET13” for a clear liquid diet (Low-Liver-*DALRD3*,

196  $p=2.98 \times 10^{-5}$ ). In individuals with High BMI, upregulation of ARIH2 was associated with code “82565” for  
197 a creatinine serum lab order (High-Brain Amygdala-ARIH2,  $p=2.87 \times 10^{-5}$ ) and downregulation of WDR6  
198 and TMEM89 was associated with code “51701” for bladder catheter insertion (High-Artery Aorta-  
199 TMEM89,  $p=1.77 \times 10^{-5}$ ; High-Thyroid-WDR6,  $p=2.35 \times 10^{-5}$ ). Additional encounter order codes  
200 associated with AN-GReX in individuals with High BMI were “DIET50” for a renal diet, “CON65” for a  
201 consult to social worker, “PR157” for post-diagnostic catheter nursing intervention, “PRL166” for physician  
202 notification, “101186” for an abdominal pain panel, “NUR17” for pain assessment, “82040” for albumin  
203 blood measurement, and “NUR463” for obtaining height and weight measures (**Table S13**).

204

### 205 **Family History**

206 After QC a total of 144 phenotypes were available from family history data derived from the EHR (**Table**  
207 **S14**). Family history phenotypes were initially collapsed based on degree of relatedness into “first  
208 degree”, “second degree” and “third degree” categories (see **Supplementary Methods**). Upregulation of  
209 *MGMT* was associated with a first-degree family history of HIV infection in both the overall cohort ( $p<3.33$   
210  $\times 10^{-4}$ ) and in individuals with low BMI ( $p<7.93 \times 10^{-4}$ ) across multiple tissues. This association passed the  
211 phenotype-wide threshold of  $p=1.64 \times 10^{-5}$  in individuals with low BMI (Low-Brain Hippocampus-*MGMT*,  
212  $p=6.93 \times 10^{-7}$ ; Low-Subcutaneous Adipose-*MGMT*,  $p=7.53 \times 10^{-6}$ ; Low-Brain Caudate basal ganglia-  
213 *MGMT*,  $p=1.09 \times 10^{-5}$ ; Low-Brain Amygdala-*MGMT*,  $p=1.14 \times 10^{-5}$ ; Low-Colon Sigmoid-*MGMT*,  $p=1.46 \times$   
214  $10^{-5}$ ).

215

### 216 **Medications**

217 After QC, a total of 1,086 unique medications/drug components were tested for association with AN-  
218 GReX. All associations with medications are shown in **Table S11**. In the overall cohort, upregulation of  
219 MHC-gene *CLIC1* was associated with multiple insulin- and diabetes-related medications including  
220 glucagon (Spleen-*CLIC1*,  $p=4.20 \times 10^{-9}$ ), insulin aspart, insulin detemir, insulin degludec, insulin glulisine,  
221 insulin glargine, insulin lispro, insulin isophane, regular insulin and liraglutide (Subcutaneous Adipose-  
222 *CLIC1*,  $p<3.27 \times 10^{-5}$ ). Upregulation of *KREMEN1* and *RBM6*, and downregulation of *PFKFB4* were also  
223 associated with insulin- and diabetes-related phenotypes (Insulin aspart-Liver-*KREMEN1*,  $p=2.81 \times 10^{-5}$ ;



224 insulin glargine-Liver-*KREMEN1*,  $p=4.16 \times 10^{-5}$ ; insulin isophane-Liver-*KREMEN1*,  $p=4.31 \times 10^{-5}$ ;  
225 linagliptin-Skin Not Sun Exposed-*PFKFB4*,  $p=3.91 \times 10^{-5}$ ; insulin isophane-Brain Substantia Nigra-*RBM6*,  
226  $p=3.96 \times 10^{-5}$ ). In the overall cohort, downregulation of *RNF123* was associated with the benzodiazepine  
227 sedative temazepam (Artery Aorta-*RNF123*,  $p=2.76 \times 10^{-6}$ ), stimulant laxative sennosides (Esophagus  
228 Mucosa-*RNF123*,  $p=1.33 \times 10^{-5}$ ; Skeletal Muscle-*RNF123*,  $p=6.88 \times 10^{-6}$ ), and diuretic  
229 hydrochlorothiazide (Esophagus Muscularis-*RNF123*,  $p=3.73 \times 10^{-5}$ ). Upregulation of *KREMEN1* was also  
230 associated with the hydrochlorothiazide (Adipose Visceral Omentum-*KREMEN1*,  $p=4.55 \times 10^{-5}$ ).  
231 Downregulation of *PFKFB4* was associated with type 2 diabetes medication empagliflozin (Skin Not Sun  
232 Exposed-*PFKFB4*,  $p=1.58 \times 10^{-5}$ ) and anti-diarrheal loperamide (Skin Not Sun Exposed-*PFKFB4*,  $p=2.19$   
233  $\times 10^{-5}$ ). Additional overall AN-GReX associations with medications include antibiotic bacitracin (DLPFC-  
234 *C3orf62*,  $p=4.28 \times 10^{-5}$ ), SSRI antidepressant sertraline (Brain Cerebellum-*MGMT*,  $p=2.53 \times 10^{-5}$ ),  
235 analgesic salicylic acid (Brain Caudate basal ganglia-*NICN1*,  $p=1.90 \times 10^{-5}$ ), HIV antiviral lopinavir (Brain  
236 Hippocampus-*SLC26A6*,  $p=1.72 \times 10^{-6}$ ) and immunosuppressant chloroquine (Cells Transformed  
237 lymphocytes-*SLC2A10*,  $p=3.71 \times 10^{-5}$ ).

238  
239 Within the BMI-stratified groups, we find that *CLIC1* upregulation is similarly associated with glucagon in  
240 individuals in the Mid BMI group (Mid-Spleen-*CLIC1*,  $p=2.09 \times 10^{-6}$ ), and the association of *CLIC1* GReX  
241 with glucagon remains fairly similar across BMI groups (**Figure S8**). Chemotherapy drug Paclitaxel is  
242 associated with upregulation of *SUOX* (Mid-DGN Whole Blood-*SUOX*,  $p=1.15 \times 10^{-6}$ ) and upregulation of  
243 *PFKFB4* with anti-muscarinic drug mirabegron in Mid BMI individuals (Mid-Esophagus Mucosa-*PFKFB4*,  
244  $p=1.77 \times 10^{-6}$ ). In individuals of High BMI, downregulation of *MST1* was associated with anti-diarrheal  
245 hormone octreotide (High-Adrenal gland-*MST1*,  $p=4.71 \times 10^{-6}$ ) and downregulation of *PFKFB4* was  
246 associated with antidiabetic repaglinide and anti-tremor and gut antispasmodic Hyoscyamine  
247 (Repaglinide-High-Skin Sun Exposed-*PFKFB4*,  $p=7.92 \times 10^{-6}$ ; Hyoscyamine-High-Skin Not Sun Exposed-  
248 *PFKFB4*,  $p=1.39 \times 10^{-5}$ ). Among Low BMI individuals, top associations include upregulation of *GPX1* with  
249 prescription for lanolin oil (Low-Adipose Visceral Omentum-*GPX1*,  $p=8.25 \times 10^{-6}$ ; Low-Ovary-*GPX1*,  
250  $p=3.33 \times 10^{-6}$ ). Additionally, downregulation of *USP19* was associated with osteoporosis drug Teriparatide

251 in individuals with Low BMI (Low-Pituitary-*USP19*,  $p=7.84 \times 10^{-6}$ ). Additional associations of AN-GReX  
252 with medications are found in **Table S11**.

253

### 254 ***OBGYN History***

255 OBGYN phenotypes were extracted from the EHR and contained the following categories along with date  
256 of outcome: abortion, current pregnancy, ectopic pregnancy, para (parity), gravida, preterm birth,  
257 spontaneous abortion, to-term birth and therapeutic abortion. PheWAS were run on two (iterations) of the  
258 data: (1) Overall having any phenotype as a categorical TRUE/FALSE and (2) continuous counts of each  
259 phenotype (Sample numbers are available in **Table S18**). Upregulation of *KREMEN1* in individuals with  
260 high BMI was associated with overall parity, or the number of births per gestation (Subcutaneous  
261 adipose-*KREMEN1*,  $p=1.16 \times 10^{-4}$ ). Downregulation of *SLC26A10* was also associated with parity, but in  
262 individuals of low BMI (Subcutaneous adipose-*SLC26A10*,  $p=2.03 \times 10^{-5}$ ). All associations are shown in  
263 **Table S16**. For continuous measures of OBGYN outcomes, *CLIC1* upregulation was associated with  
264 greater counts of preterm pregnancies in the overall cohort (Adipose Subcutaneous-*CLIC1*,  $p=4.05 \times 10^{-6}$ )  
265 and in High BMI individuals (High-Adipose Subcutaneous-*CLIC1*,  $p=1.55 \times 10^{-8}$ ). Downregulation of  
266 *LAMB2* was also associated with number of preterm pregnancies in High BMI individuals (High-Adipose  
267 Subcutaneous-*LAMB2*,  $p=2.68 \times 10^{-6}$ ). Additional associations of AN-GReX with continuous OBGYN  
268 outcomes are described in **Table S16**.

269

### 270 ***Personal History***

271 We tested a total of 35 phenotypes listed as “Personal History of Disease” in BioMe™ (**Table S16**).  
272 Upregulation of *ARIH2*, *C3orf62*, *CCDC36*, *CELSR3*, *DALRD3*, *NCKIPSD*, *NDUFAF3*, *NICN1* and  
273 *P4HTM*, and downregulation of *CCDC71*, *GPX1* and *WDR6*, were associated with personal history of  
274 Lupus in the overall cohort, as well as in individuals with Mid BMI, in multiple tissues (Overall,  $p<1.42 \times$   
275  $10^{-3}$ ; Mid,  $p<1.41 \times 10^{-3}$ )(**Figure S15**). All of these genes fall within the chromosome 3 locus from our S-  
276 PrediXcan results (**Figure 1, Table S4**). Additionally, MHC-gene *CLIC1* was also associated with a  
277 personal history of Lupus in the overall cohort (Skeletal Muscle-*CLIC1*,  $p=7.57 \times 10^{-4}$ ; Spleen-*CLIC1*,  
278  $p=6.72 \times 10^{-4}$ ; Subcutaneous Adipose-*CLIC1*,  $p=2.01 \times 10^{-4}$ ). In individuals with Mid BMI, upregulation of

279 *ARIH2*, *C3orf62*, *CCDC36*, *CELSR3*, *DALRD3*, *NCKIPSD*, *NICN1*, *P4HTM* and *USP19*, and  
280 downregulation of *CCDC71*, *GPX1*, *LAMB2*, and *WDR6*, was associated with a personal history of high  
281 blood pressure ( $p < 1.42 \times 10^{-3}$ ). Similarly, upregulation of *ARIH2*, *CCDC36*, *CELSR3*, *DALRD3*,  
282 *NCKIPSD*, *NDUFAF3*, *P4HTM* and downregulation of *WDR6* was associated with a personal history of  
283 kidney disease in individuals with Mid BMI ( $p < 1.39 \times 10^{-3}$ ). Additional associations are shown in **Table**  
284 **S15**.

285

### 286 **Social History (additional results)**

287 Sample numbers for social history phenotypes can be found in **Tables S19** through **S22**. Phenotypes of  
288 sexual history, such as sexual activity, contraceptive use and type, as well as information about sexual  
289 partner, were derived from the social history questionnaire. A total of eight phenotypes were tested for  
290 association with AN-GReX\*: (1) Sexually active (Y/N) (2) Self-reported female or male partner (3)  
291 Contraceptive method: abstinence, condom, injection, IUD, and pill (\*phenotypes are categorized as Y/N  
292 or T/F). In the overall cohort, upregulation of *RBM6* and *SEMA3F* and downregulation of *MST1R* and  
293 *RNF123* were associated with being sexually active across multiple tissues (*RBM6*,  $p < 5.46 \times 10^{-3}$ ;  
294 *SEMA3F*,  $p < 4.51 \times 10^{-3}$ ; *MST1R*,  $p < 4.60 \times 10^{-3}$ ; *RNF123*,  $p < 4.50 \times 10^{-3}$ ). Within our stratified BMI  
295 analyses, downregulation of *APEH* was associated with being sexually active in individuals of High BMI  
296 (High-Esophagus Muscularis-*APEH*,  $p = 4.63 \times 10^{-5}$ ). Additionally in individuals of High BMI, upregulation  
297 of *GPX1* was associated with IUD use (High-Esophagus Mucosa-*GPX1*,  $p = 8.11 \times 10^{-5}$ ). All associations  
298 are described in **Table S9**.

299

### 300 **Anthropometric traits and Vital signs**

301 Vital signs were measured for individuals at most if not all encounters with the healthcare system.  
302 Measurements of blood pressure, height, pain score and location, pulse, pulse oximetry, respirations,  
303 temperature and weight were recorded for each individual for each encounter. Vital sign measurements  
304 were standardized and QC of these measurements is described in the **Supplementary Methods**. Full  
305 results for vital signs are shown in **Table S6**.

306

### 307 *Blood Pressure*

308 Blood pressure measures were split into three factors: diastolic pressure, systolic pressure, and pulse  
309 pressure (see **Supplementary Methods**), with highest ever measure, lowest ever measure, mean  
310 measure and variance calculated for each phenotype. In the overall cohort, upregulation of *RBM6* and  
311 downregulation of *MST1R* and *RNF123* were associated with diastolic and systolic highest  
312 measurements in multiple tissues (Diastolic highest-*RBM6*,  $p < 9.70 \times 10^{-4}$ ; Diastolic highest-*MST1R*,  
313  $p < 9.27 \times 10^{-4}$ ; Diastolic highest-*RNF123*,  $p < 8.56 \times 10^{-4}$ ; Systolic highest-*RBM6*,  $p < 9.74 \times 10^{-4}$ ; Systolic  
314 highest-*MST1R*,  $p < 7.08 \times 10^{-4}$ ; Systolic highest-*RNF123*,  $p < 8.89 \times 10^{-4}$ ). Upregulation of *NCKIPSD*,  
315 *NDUFAF3*, and *P4HTM*, and downregulation of *WDR6* were associated with lowest systolic pressure in  
316 the overall cohort (multiple tissues,  $p < 9.68 \times 10^{-4}$ ). BMI-stratified associations are described in the full  
317 summary statistics in **Table S6**.

318

### 319 *Height*

320 Height for individuals in BioMe™ was standardized to centimeters units of measure (see **Supplementary**  
321 **Methods**). In the overall cohort, there were four genes associated with measures of mean height.  
322 Upregulation of *CLIC1*, *GPR75* and *LINC00324* and downregulation of *CTNNB1* were associated with  
323 mean height (Adipose Subcutaneous-*CLIC1*,  $p = 1.39 \times 10^{-5}$ ; Adipose Subcutaneous-*GPR75*,  $p = 3.51 \times 10^{-4}$ ;  
324 Artery Tibial-*GPR75*,  $p = 5.07 \times 10^{-4}$ ; Skin Sun Exposed-*LINC00324*,  $p = 6.51 \times 10^{-4}$ ; Brain Amygdala-  
325 *CTNNB1*,  $p = 2.28 \times 10^{-4}$ ; Brain Caudate basal ganglia-*CTNNB1*,  $p = 1.67 \times 10^{-4}$ ; Brain Putamen basal  
326 ganglia-*CTNNB1*,  $p = 4.65 \times 10^{-4}$ ). *GPR75* and *CLIC1* upregulation were also associated with mean height  
327 among the Mid BMI individuals (Mid-Adipose Subcutaneous-*CLIC1*,  $p = 4.31 \times 10^{-4}$ ; Mid-Artery Tibial-  
328 *GPR75*,  $p = 1.44 \times 10^{-4}$ ). Full summary statistics are available in **Table S6**.

329

### 330 *Pain Score and Location (Additional results)*

331 Pain score and location measurements were described within the vital sign files from the BioMe™  
332 BRSPD files. QC of pain score and pain location phenotypes are available in the **Supplementary**  
333 **Methods**. Final phenotypes available for pain score include highest ever, sum pain score and mean pain  
334 score. Pain location resulted in a total of 25 location phenotypes: abdomen, ankle, back, breast, chest,

335 costal left, costal right, elbows, feet, generalized, groin, hands, head, knees, left leg, lower extremities,  
336 neck, pelvis, perineum, right leg, sacrum, shoulder, throat, upper extremities and wrist. Pain score by  
337 location phenotypes included measures of highest ever, sum and mean pain scores for each location  
338 type.

339

340 Upregulation of *SLC2A10* was associated with mean pain score in the overall cohort (Adrenal Gland-  
341 *SLC2A10*,  $p=9.94 \times 10^{-4}$ ). Upregulation of *SLC2A10* was also associated with mean pain score in Low  
342 BMI individuals (Low-Adrenal Gland-*SLC2A10*,  $p=6.54 \times 10^{-5}$ ). In High BMI individuals, downregulation of  
343 *MGMT* was associated with mean pain score in multiple tissues (High-*MGMT*,  $p<9.48 \times 10^{-4}$ ).

344 Downregulation of *PROS1* was also associated with mean pain score in the High BMI group (High-Artery  
345 Aorta-*PROS1*,  $p=8.06 \times 10^{-4}$ ). Downregulation of *CLIC1* and downregulation of *MGMT* were associated  
346 with pain score sum in Low and High BMI groups respectively (Low- Testis-*CLIC1*,  $p=2.83 \times 10^{-4}$ ; High-  
347 Spleen-*MGMT*,  $p=1.85 \times 10^{-5}$ ).

348

349 For measures of pain location only, many genes were associated with pain location in the overall cohort,  
350 as well as among the stratified BMI groups. In the overall cohort, upregulation of *ARIH2*, *C3orf62*,  
351 *DALRD3*, *NCKIPSD* and downregulation of *GPX1* and *WDR6* were associated with throat pain. *CTNNB1*  
352 was associated with back (upregulation), chest (upregulation) and left leg pain (downregulation).

353 Upregulation of *MST1R* and *RNF123* was associated with breast pain in the overall cohort, and  
354 upregulation of *CHAC2* and *P4HTM*, and downregulation of *LINC00324* were associated with costal left  
355 pain. All summary statistics for AN-GReX associations with pain location are located in **Table S10**. Within  
356 our stratified BMI groups, we see large numbers of associations of generalized pain location and foot pain  
357 with Low BMI individuals. There are a total of 55 gene-tissue associations of AN-GReX with generalized  
358 pain, and 129 associations with foot pain (Generalized  $p<1.88 \times 10^{-3}$ , Foot  $p <2.03 \times 10^{-3}$ ). Some of the  
359 genes included in those associations include *RBM6* upregulation with generalized pain (32 associations,  
360  $p<1.16 \times 10^{-3}$ ), *MST1R* downregulation with generalized pain (13 associations,  $p<1.07 \times 10^{-3}$ ), *CCDC36*  
361 downregulation with foot pain (19 associations,  $p<1.76 \times 10^{-3}$ ), *NCKIPSD* downregulation with foot pain

362 (33 associations,  $p < 1.90 \times 10^{-3}$ ), and upregulation of *WDR6* with foot pain (32 associations,  $p < 2.03 \times 10^{-3}$ ). Full summary statistics for each body location are available in **Table S10**.

364

365 When merging pain score with pain location, multiple AN genes were associated with measure of pain in  
366 various bodily locations (**Table S10**). In the overall cohort, upregulation of *CTNNB1*, *TMEM89* and  
367 *TNFSF12* was associated with throat pain score sum (Nerve Tibial-*CTNNB1*,  $p = 4.92 \times 10^{-10}$ ; Artery Aorta-  
368 *TMEM89*,  $p = 1.25 \times 10^{-5}$ ; Brain Cerebellar Hemisphere-*TMEM89*,  $p = 2.39 \times 10^{-6}$ ; Nerve Tibial-*TNFSF12*,  
369  $p = 8.20 \times 10^{-7}$ ). Upregulation of *KREMEN1* was associated with highest ever elbow pain as well as mean  
370 elbow pain measures (Highest-Artery Aorta-*KREMEN1*,  $p = 3.62 \times 10^{-6}$ ; Mean-Artery Aorta-*KREMEN1*,  
371  $p = 1.43 \times 10^{-6}$ ). Downregulation of *ASB3* and *SEMA3F*, and upregulation of *LAMB2* were associated with  
372 knee pain score sum (Cells EBV-transformed-*ASB3*,  $p = 3.81 \times 10^{-5}$ ; Brain Substantia nigra-*SEMA3F*,  
373  $p = 2.03 \times 10^{-6}$ ; DGN Whole Blood-*LAMB2*,  $p = 3.86 \times 10^{-5}$ ). Upregulation of *EBF3* was associated with hand  
374 pain score sum, while downregulation of *PFKFB4* and *SPINK8* were associated with back pain score sum  
375 and costal left pain score sum respectively (**Table S10**). Upregulation of *CTNNB1*, *SLC2A10*, *SPINK8*,  
376 *TNFSF12* and downregulation of *KREMEN1* were associated with knee pain score measures.

377

378 Within the stratified BMI groups, many genes were associated with various pain scores and locations.  
379 *MST1* downregulation was associated with highest neck pain score in Mid BMI individuals (Multiple  
380 tissues,  $p < 4.00 \times 10^{-5}$ ). Among the Low BMI individuals, six genes were associated with abdomen pain  
381 score sum: *CLIC1*, *EBF3*, *GPR75*, *NICN1*, *SLC2A10* and *TNFSF12* (**Table S10**). Upregulation of *ARIH2*,  
382 *MST1* and *NICN1* in Low BMI individuals was associated with right leg pain score sum. In High BMI  
383 individuals, *CTNNB1*, *KREMEN1*, *SLC2A10*, *SPINK8* and *TNFSF12* were associated with measures of  
384 knee pain, and *PFKFB4*, *SUOX* and *NICN1* were associated with back pain, head pain, and ankle pain  
385 respectively. All summary statistics for pain score by location can be found in **Table S10**.

386

### 387 *Pulse*

388 Pulse measurements of beats per minute (bpm) were measured as the other vital sign continuous  
389 measurements as highest ever, lowest ever, mean and variance (**Supplemental Methods**).

390 Downregulation of two genes, *NCKIPSD* and *TNFSF12*, were associated with mean pulse and pulse  
391 variance respectively in the overall cohort (Colon Transverse-*NCKIPSD*,  $p=1.60 \times 10^{-4}$ ; Brain Substantia  
392 nigra-*TNFSF12*,  $p=9.20 \times 10^{-4}$ ). Among individuals of Low BMI, a different set of genes is associated with  
393 measures of pulse. Downregulation of *ARIH2* was associated with highest pulse, while downregulation of  
394 *MST1R* and *RNF123* was associated with mean pulse (Low-Liver-*ARIH2*,  $p=2.57 \times 10^{-4}$ ; Low-Colon  
395 Sigmoid-*MST1R*,  $p=5.81 \times 10^{-4}$ ; Low-Pituitary-*RNF123*,  $p=5.65 \times 10^{-4}$ ). Upregulation of *ARIH2OS* was  
396 associated with mean pulse in Low BMI individuals as well (Low-Nerve Tibial-*ARIH2OS*,  $p=7.52 \times 10^{-4}$ ).  
397 Full summary statistics are located in **Table S6**.

398

### 399 *Pulse Oximetry*

400 AN-GReX was not significantly associated with measures of pulse oximetry in the overall BioMe™ cohort,  
401 however, when we stratified by BMI, we did see significant associations of AN-GReX with pulse oximetry  
402 within the High and Low BMI individuals. Downregulation of *MGMT* was associated with mean pulse  
403 oximetry measurements in High BMI individuals (High-Brain Cerebellar Hemisphere-*MGMT*,  $p=6.84 \times 10^{-4}$ ),  
404 while downregulation of *GPX1* and upregulation of *ARIH2* were associated with pulse oximetry  
405 variance in Low BMI individuals (Low-Ovary-*GPX1*,  $p=1.95 \times 10^{-4}$ ; Low-Brain Amygdala-*ARIH2*,  $p=9.03 \times$   
406  $10^{-4}$ ). Full summary statistics are located in **Table S6**.

407

### 408 *Respirations*

409 Associations of AN-GReX with respirations, or breaths per minute, were measured using highest ever,  
410 lowest ever, mean and variance for the respiration phenotypes (**Supplemental Methods**).  
411 Downregulation of *ARIH2*, *CCDC36*, and *MST1R*, and upregulation of *CCDC71*, *GPX1*, *RBM6* and  
412 *WDR6* were associated with measures of highest ever respiration rate (Multiple tissues,  $p<9.84 \times 10^{-4}$ ,  
413 **Table S6**). Additionally, downregulation of *CCDC36* and *P4HTM*, and upregulation of *GPX1*, were  
414 associated with mean respiration rate among the overall cohort (Multiple tissues,  $p<8.53 \times 10^{-4}$ ). Among  
415 the BMI stratified groups, we find that downregulation of *GPX1* and upregulation of *NICN1* is associated  
416 with lowest ever respiration rates in High BMI individuals (Multiple tissues,  $p<8.99 \times 10^{-4}$ ). Among Low  
417 BMI individuals, we see similar patterns of association of AN-GReX with respirations as we saw in the

418 overall cohort. Downregulation of *ARIH2*, *NCKIPSD*, and *CCDC36*, and upregulation of *CCDC71* and  
419 *WDR6* are associated with highest respiration rate in the Low BMI individuals (Multiple tissues,  $p < 9.93 \times$   
420  $10^{-4}$ ). Full summary statistics are located in **Table S6**.

421

## 422 *Temperature*

423 Temperature measurements were standardized to degrees Celsius (**Supplemental Methods**), and  
424 highest ever, lowest ever, mean and variance calculated. In the overall cohort, upregulation of *MGMT*  
425 was associated with mean temperature (Testis-*MGMT*,  $p = 5.63 \times 10^{-4}$ ). Among individuals in the Mid BMI  
426 group, downregulation of *EBF3* was associated with highest ever temperature (DLFPC-*EBF3*,  $p = 7.24 \times$   
427  $10^{-4}$ ; Ovary-*EBF3*,  $p = 7.15 \times 10^{-4}$ ). Full summary statistics are located in **Table S6**.

428

## 429 *Weight (Additional results)*

430 Regression lines (with confidence intervals) for individual *CLIC1*-GReX plotted against highest and lowest  
431 recorded weight measures are shown in **Figure S16 and S17**.

432

433 Multiple genes were associated with weight change over time, which was measured by kg change per  
434 year, in all four BMI groups. Downregulation of *ARIH2*, *NCKIPSD*, *NDUFAF3* and *P4HTM* and  
435 upregulation of *WDR6* were associated with weight change over time in Overall, High and Low BMI  
436 groups in multiple tissues (**Figure S4, Table 3**). Downregulation of *RNF123* was associated with weight  
437 change over time in the overall cohort and in individuals with High BMI (Overall-Uterus-*RNF123*,  $p = 3.18 \times$   
438  $10^{-4}$ ; High-Artery Aorta-*RNF123*,  $p = 3.59 \times 10^{-4}$ ), and upregulation of *RNF123* was associated with weight  
439 change in individuals with Mid and Low BMI (Mid-Brain Amygdala-*RNF123*,  $p = 8.91 \times 10^{-5}$ ; Mid-Cells  
440 Transformed Fibroblasts-*RNF123*,  $p = 2.90 \times 10^{-4}$ ; Low-Vagina-*RNF123*,  $p = 5.16 \times 10^{-4}$ ). Upregulation of  
441 *CCDC71* and *DHFR2*, and downregulation of *DALRD3* were associated with weight change over time in  
442 High and Low BMI individuals (High-Brain Cerebellar Hemisphere-*CCDC71*,  $p = 4.71 \times 10^{-4}$ ; High-Brain  
443 Cerebellum-*CCDC71*,  $p = 1.67 \times 10^{-4}$ ; High-Spleen-*CCDC71*,  $p = 2.43 \times 10^{-4}$ ; High-Thyroid-*CCDC71*,  
444  $p = 7.53 \times 10^{-4}$ ; Low-Tibial Nerve-*CCDC71*,  $p = 6.82 \times 10^{-4}$ ; High-DGN Whole Blood-*DHFR2*,  $p = 3.47 \times 10^{-4}$ ;  
445 Low-DGN Whole Blood-*DHFR2*,  $p = 7.48 \times 10^{-4}$ ; High-Multiple tissues-*DALRD3*,  $p < 8.21 \times 10^{-4}$ ; Low-Brain



446 Cerebellum-*DALRD3*,  $p=5.85 \times 10^{-4}$ ; Low-Esophagus Gastroesophageal Junction-*DALRD3*,  $p=5.01 \times 10^{-4}$ .  
447 <sup>4</sup>). In individuals with High BMI, downregulation of *C3orf62*, *CCDC36*, *CELSR3* and *PROS1* were  
448 associated with weight change over time (High-DLPFC-*C3orf62*,  $p=8.59 \times 10^{-4}$ ; High-Adipose Visceral  
449 Omentum-*C3orf62*,  $p=6.45 \times 10^{-4}$ ; High-DGN Whole Blood-*C3orf62*;  $p=7.19 \times 10^{-4}$ ; High-DGN Whole  
450 Blood-*CCDC36*,  $p=3.05 \times 10^{-6}$ ; High-Subcutaneous Adipose-*CCDC36*,  $p=1.40 \times 10^{-5}$ ; High-Tibial  
451 Nerve-*CELSR3*,  $p=1.09 \times 10^{-4}$ ; High-Whole Blood-*PROS1*,  $p=3.46 \times 10^{-4}$ ). Full summary associations of  
452 AN-GReX with weight change over time are shown in **Table 3**.

453

#### 454 ***Distribution of CLIC1-GReX by BMI***

455 To assess whether our BMI-group specific *CLIC1*-GReX associations are driven by differences in the  
456 distribution of GReX measures in these BMI subgroups, we tested for pairwise differences in the  
457 distribution of *CLIC1*-GReX for four tissues (Breast Mammary Tissue, Spleen, Subcutaneous Adipose  
458 and Whole Blood) using the Kolmogorov-Smirnov test (**Figure S18**). We found no significant difference in  
459 the distribution of *CLIC1*-GReX across BMI groups for any tissue ( $p_{\text{Significance}} < 0.0167$ ; Breast Mammary  
460 Tissue,  $p_{\text{KS}} > 0.0495$ ; Spleen,  $p_{\text{KS}} > 0.0368$ ; Subcutaneous Adipose,  $p_{\text{KS}} > 0.9262$ ; Whole Blood,  $p_{\text{KS}} > 0.2726$ ).

461

462

463 **SUPPLEMENTARY FIGURES AND TABLES**

464

465 **Figure S1: BMI stratification of the BioMe™ cohort.** We stratified the BioMe™ individuals into three  
466 BMI groups: High, Mid and Low, based on the distribution of BMI within each ancestry by sex. Individuals  
467 whose BMI fell above the 3<sup>rd</sup> quartile of BMI distribution were assigned to the High BMI group, those  
468 whose BMI fell below the 1<sup>st</sup> quartile were assigned to Low, and those between the 1<sup>st</sup> and 3<sup>rd</sup> quartiles of  
469 the distribution were assigned to the Mid BMI group.

470

471 **Figure S2: Distribution of BMI by BioMe™ ancestry and sex.** BMI distributions are plotted by sex  
472 (female, male) for each ancestry group. Ancestry is coded as: AA (African), EA (European), ESA (East  
473 Asian), HA (Hispanic), NA (Native American), SAS (South Asian).

474

475 **Figure S3: Forest plot of Overall weight change over time associations with AN-GReX.** Effect  
476 estimate and 95% CI measures for AN-GReX (Gene-Tissue) associated with the measurement of weight  
477 change over time (measured as kg/year) in the overall BioMe™ cohort. Tissue-specific significance  
478 threshold set at  $p < 0.001$ .

479

480 **Figure S4: Forest plot of Overall weight change over time associations with AN-GReX across three**  
481 **BMI groups.** Effect estimate and 95% CI measures for AN-GReX (Gene-Tissue) associated with the  
482 measurement of weight change over time (measured as kg/year) in four BMI groups: Overall, High BMI,  
483 Mid BMI and Low BMI. Tissue-specific significance threshold set at  $p < 0.001$ .

484

485 **Figure S5: Forest plot of Encounter Diagnosis associations across BMI groups.** Effect estimates  
486 and 95% CI for the associations of AN-GReX with Encounter Diagnosis ICD-10 codes across the four  
487 BMI groups: Overall, High BMI, Mid BMI and Low BMI. Diagnosis code and description, as well as Gene-  
488 Tissue of association, given on the Y-axis. Experiment-wide significance threshold set at  $p < 3.06 \times 10^{-7}$ .

489

490 **Figure S6: Forest plot of Phecode associations across BMI groups.** Effect estimates and 95% CI for  
491 the associations of AN-GReX with phecodes across the four BMI groups: Overall, High BMI, Mid BMI and  
492 Low BMI. Phecode and description, as well as Gene-Tissue of association, given on the Y-axis.  
493 Experiment-wide significance threshold set at  $p < 3.06 \times 10^{-7}$ .

494

495 **Figure S7: Forest plot of Substance Use AN-GReX associations across BMI groups.** Effect  
496 estimates and 95% CI for the associations of AN-GReX with substance use phenotypes across the four  
497 BMI groups: Overall, High BMI, Mid BMI and Low BMI. Tissue-specific significance threshold set at  
498  $p < 0.001$ .

499

500 **Figure S8: Forest plot of *CLIC1*-Spleen association with Glucagon medication across BMI groups.**  
501 Effect estimates and 95% CI for the associations of *CLIC1*-Spleen GReX with Glucagon medication  
502 across the four BMI groups: Overall, High BMI, Mid BMI and Low BMI. Filled circles indicate Bonferroni-  
503 significant associations. Tissue-specific significance threshold set at  $p < 5.26 \times 10^{-5}$ .

504

505 **Figure S9: Graphical depiction of S-PrediXcan and PrediXcan transcriptomic imputation and**  
506 **pheWAS analyses.** We used S-PrediXcan predictor models for 50 different tissue types to impute  
507 genetically-regulated gene expression (GReX) in the Watson, *et. al*, 2019 AN GWAS and found 47 genes  
508 whose GReX was associated with Anorexia Nervosa. We then imputed GReX for those 47 AN genes in  
509 our BioMe™ cohort and performed a phenome-wide association study (pheWAS) across available EHR  
510 phenotypes. The pheWAS analyses were run within each ancestral population and then meta-analyzed  
511 using an inverse-variance approach in METAL. Secondary analyses included stratifying individuals in  
512 BioMe by BMI and running the pheWAS analyses within each BMI group.

513

514 **Figure S10: Descriptive statistics for continuous measures of substance use.** Continuous  
515 phenotypes for alcohol, illicit drug and tobacco use. Alcohol use was measured as number of ounces of  
516 alcohol consumed per week, Illicit drug use was measured as number of times used (frequency), and  
517 tobacco use was measured as number of years usage of tobacco and number of packs of cigarettes  
518 smoked per day.

519

520 **Figure S11: Descriptive statistics for continuous OBGYN outcome phenotypes.** Counts for the  
521 presence of nine OBGYN phenotypes: (1) Current pregnancy (2) Parity (number of pregnancies with  
522 outcome of live birth) (3) Gravida (number of pregnancies regardless of birth outcome) (4) Births to term  
523 (5) Preterm births (6) Ectopic pregnancies (7) Abortion (8) Spontaneous abortion (miscarriage) (9)  
524 Therapeutic abortion.

525

526 **Figure S12: Descriptive statistics for vital sign measurement phenotypes.** Vital sign measurements  
527 for blood pressure (systolic, diastolic and pulse pressure), height (cm), pulse (beats per minute), pulse  
528 oximetry (%), respirations (breaths per minute) and temperature (degrees Celsius).

529

530 **Figure S13: Descriptive statistics of weight phenotypes.** Distribution of weight measurements (in kg)  
531 of highest recorded and lowest recorded weight in BioMe™. Weight change over time was measured as  
532 average kg change per year.

533

534 **Figure S14: Descriptive statistics for pain score and pain location phenotypes.** (A) Histograms of  
535 pain score (regardless of pain location) recorded on a 0 to 10 scale; measurements used for pheWAS  
536 analyses included highest recorded pain score, mean pain score and sum of all pain score  
537 measurements. Mean pain score is indicated by the dotted line. (B) Violin plots of pain score by location  
538 measured as highest recorded pain score, mean pain score, and sum of pain scores for each pain  
539 location. Mean pain score measurements for each phenotype is indicated by the red dot.

540  
541 **Figure S15: Manhattan plot of association of Personal History phenotypes with AN-GReX for four**  
542 **BMI groups.** Personal History phenotypes (N=35; X-axis) and association with AN-GReX (-log<sub>10</sub>(p) on Y-  
543 axis) for four BMI groups: Overall, High BMI, Mid BMI, and Low BMI. Experiment-wide  $p=2.86 \times 10^{-5}$ ;  
544 Tissue-specific  $p=1.43 \times 10^{-3}$ .

545  
546 **Figure S16: Regression plots for individual CLIC1-GReX versus lowest and highest weight**  
547 **measures.** Linear regression model lines with 95% confidence intervals for individual CLIC1-GReX  
548 measures for (A) Subcutaneous Adipose, (B) Breast Mammary Tissue, (C) Spleen, and (D) Whole Blood  
549 tissues for lowest recorded weight and highest recorded weight measures (kg). Forest plots of effect  
550 estimates for associations of CLIC1-GReX with lowest and highest recorded weight.

551  
552 **Figure S17: CLIC1-GReX versus lowest recorded weight measurement (kg).** (A) Individual CLIC1-  
553 GReX measures versus lowest recorded weight measurements for breast and spleen tissues with  
554 regression line and 95% confidence interval. (B) Individual CLIC1-GReX measures versus lowest  
555 recorded weight measurements (kg) for Breast Mammary tissue and Spleen, with regression line only and  
556 95% confidence interval.

557  
558 **Figure S18: Distribution of CLIC1-GReX by BMI group.** Density plots of CLIC1-GReX for (A) Breast  
559 Mammary, (B) Spleen, (C) Subcutaneous Adipose, and (D) Whole Blood tissues by three BMI groups,  
560 High, Mid and Low. P value for KS test for significance shown for each tissue.

561  
562 **Table S1: Bonferroni-corrected significance thresholds for each tissue model tested for S-**  
563 **PrediXcan.** Indicates number of genes tested per tissue, with p value for tissue-specific significance set  
564 at  $p=0.05/N_{\text{Genes}}$ .

565  
566 **Table S2: BMI stratification values by BioMe™ ancestry.** BMI values used for determining assignment  
567 to High, Mid or Low BMI groups for each ancestral population and sex. High BMI range indicates the

568 values above the 3<sup>rd</sup> quartile. Low BMI indicates the BMI values below the 1<sup>st</sup> quartile, and Mid shows the  
569 BMI range between the 1<sup>st</sup> and 3<sup>rd</sup> quartiles of BMI distribution.

570

571 **Table S3: Sample numbers for each BMI group.** Sample numbers indicated for each BMI group after  
572 stratification. Ancestry is coded as: AA (African), EA (European), ESA (East Asian), HA (Hispanic), NA  
573 (Native American), SAS (South Asian).

574

575 **Table S4: Full summary statistics for S-PrediXcan transcriptomic imputation of the PGC-AN**  
576 **GWAS<sup>9</sup>.** Gene-level summary statistics for transcriptomic imputation of AN-GWAS ( $N_{\text{Cases}}=16,992$ ,  
577  $N_{\text{Controls}}=55,525$ ) using S-PrediXcan models for CMC DLPFC, DGN Whole Blood and 47 GTEx v7 tissues.

578

579 **Table S5: AN S-PrediXcan gene summary.** Summary description of 47 AN genes, including information  
580 on previous GWAS trait associations.

581

582 **Table S6: Vital sign pheWAS results.** GReX-Tissue-Phenotype associations for Vital Sign phenotypes  
583 (Blood pressure, Height, Pulse, Pulse Oximetry, Respirations, Temperature and Weight) across all BMI  
584 groups: Overall, High, Mid, and Low. Tissue-specific threshold set at  $p<0.001$ .

585

586 **Table S7: Encounter Diagnosis pheWAS results.** GReX-Tissue-Phenotype associations for encounter  
587 diagnosis phenotypes ( $N=2,178$ ) across all BMI groups: Overall, High, Mid, and Low. Experiment-wide p  
588 value threshold  $p= 3.06 \times 10^{-7}$ ; Tissue-specific threshold  $p= 2.30 \times 10^{-5}$ .

589

590 **Table S8: Phecode pheWAS results.** GReX-Tissue-Phenotype associations for phecode phenotypes  
591 ( $N=1,093$ ) across all BMI groups: Overall, High, Mid, and Low. Experiment-wide p value threshold  $p =$   
592  $3.06 \times 10^{-7}$ ; Tissue-specific threshold  $p= 4.57 \times 10^{-5}$ .

593

594 **Table S9: Social History pheWAS results.** GReX-Tissue-Phenotype associations for Social History  
595 phenotypes (Alcohol, Illicit Drug and Tobacco use; Sexual History) across all BMI groups: Overall, High,  
596 Mid, and Low. Tissue-specific threshold set at  $p < 0.001$ .

597

598 **Table S10: Pain Score and Location pheWAS results.** GReX-Tissue-Phenotype associations for Pain  
599 score and location phenotypes across all BMI groups: Overall, High, Mid, and Low. Tissue-specific  
600 threshold set at  $p < 0.002$ .

601

602 **Table S11: Medication pheWAS results.** GReX-Tissue-Phenotype associations for medication  
603 phenotypes (N=951) across all BMI groups: Overall, High, Mid, and Low. Tissue-specific threshold set at  
604  $p < 5.26 \times 10^{-5}$ .

605

606

607 **Table S12: Allergy pheWAS results.** GReX-Tissue-Phenotype associations for allergy phenotypes  
608 (N=113) across all BMI groups: Overall, High, Mid, and Low. Tissue-specific threshold set at  $p < 4.42 \times 10^{-4}$ .  
609 .

610

611 **Table S13: Encounter orders pheWAS results.** GReX-Tissue-Phenotype associations for Encounter  
612 order phenotypes (N=1,609) across all BMI groups: Overall, High, Mid, and Low. Tissue-specific  
613 threshold set at  $p < 3.11 \times 10^{-5}$ .

614

615 **Table S14: Family History pheWAS results.** GReX-Tissue-Phenotype associations for Family history  
616 phenotypes (N=144) across all BMI groups: Overall, High, Mid, and Low. Tissue-specific threshold set at  
617  $p < 3.47 \times 10^{-4}$ .

618

619 **Table S15: Personal History pheWAS results.** GReX-Tissue-Phenotype associations for Personal  
620 history phenotypes (N=35) across all BMI groups: Overall, High, Mid, and Low. Tissue-specific threshold  
621 set at  $p < 0.001$ .

622

623 **Table S16: OBGYN pheWAS results.** GReX-Tissue-Phenotype associations for OBGYN phenotypes  
624 (N=9) across all BMI groups: Overall, High, Mid, and Low. Tissue-specific threshold set at  $p < 0.006$ .

625

626 **Table S17: Full pheWAS summary results.** GReX-Tissue-Phenotype associations for all pheWAS  
627 phenotypes (N=6,000+) across all BMI groups: Overall, High, Mid, and Low.

628

629 **Table S18: Sample Numbers for OBGYN outcomes.** Categorical OBGYN phenotypes. Ancestry is  
630 coded as: AA (African), EA (European), ESA (East Asian), HA (Hispanic), SAS (South Asian).

631

632 **Table S19: Sample numbers for Alcohol use categorical phenotypes.** Categorical phenotypes for  
633 alcohol use in BioMe™: Never used, Not currently using, Not used, Yes using and not asked. Ancestry is  
634 coded as: AA (African), EA (European), ESA (East Asian), HA (Hispanic), SAS (South Asian).

635

636 **Table S20: Sample numbers for Illicit drug use categorical phenotypes.** Categorical phenotypes for  
637 illicit drug use in BioMe™. Ancestry is coded as: AA (African), EA (European), ESA (East Asian), HA  
638 (Hispanic), SAS (South Asian).

639

640 **Table S21: Sample numbers for categorical tobacco use phenotypes.** Categorical phenotypes for  
641 tobacco use in BioMe™: Tobacco use and type. Ancestry is coded as: AA (African), EA (European), ESA  
642 (East Asian), HA (Hispanic), SAS (South Asian).

643

644 **Table S22: Sample numbers for categorical sexual history phenotypes.** Categorical phenotypes for  
645 sexual history in BioMe™. Ancestry is coded as: AA (African), EA (European), ESA (East Asian), HA  
646 (Hispanic), SAS (South Asian).

647



1 **Eating Disorders Working Group of the Psychiatric Genomics Consortium**

2

3 Roger A. H. Adan<sup>1-3</sup>, Lars Alfredsson<sup>4</sup>, Tetsuya Ando<sup>5</sup>, Ole A. Andreassen<sup>6</sup>, Harald Aschauer<sup>7</sup>,  
4 Jessica H. Baker<sup>8</sup>, Vladimir Bencko<sup>9</sup>, Andrew W. Bergen<sup>10,11</sup>, Wade H. Berrettini<sup>12</sup>, Andreas  
5 Birgegård<sup>13</sup>, Joseph M. Boden<sup>14</sup>, Ilka Boehm<sup>15</sup>, Vesna Boraska Perica<sup>16,17</sup>, Harry Brandt<sup>18</sup>,  
6 Gerome Breen<sup>19,20</sup>, Julien Bryois<sup>13</sup>, Cynthia M. Bulik<sup>8,13,21</sup>, Roland Burghardt<sup>22</sup>, Laura Carlberg<sup>23</sup>,  
7 Matteo Cassina<sup>24</sup>, Sven Cichon<sup>25-27</sup>, Maurizio Clementi<sup>24</sup>, Jonathan R. I. Coleman<sup>19,20</sup>, Roger D.  
8 Cone<sup>28</sup>, Philippe Courtet<sup>29</sup>, Steven Crawford<sup>18</sup>, Scott Crow<sup>30</sup>, James J. Crowley<sup>31,32</sup>, Unna N.  
9 Danner<sup>2</sup>, Oliver S. P. Davis<sup>33-35</sup>, Martina deZwaan<sup>36</sup>, George Dedoussis<sup>37</sup>, Daniela Degortes<sup>38</sup>,  
10 Janiece E. DeSocio<sup>39</sup>, Danielle M. Dick<sup>40-42</sup>, Dimitris Dikeos<sup>43</sup>, Christian Dina<sup>44</sup>, Monika Dmitrzak-  
11 Weglarz<sup>45</sup>, Elisa Docampo<sup>46-48</sup>, Laramie E. Duncan<sup>49</sup>, Philibert Duriez<sup>50,51</sup>, Karin Egberts<sup>52</sup>, Stefan  
12 Ehrlich<sup>15</sup>, Geòrgia Escaramís<sup>46-48</sup>, Tõnu Esko<sup>53,54</sup>, Thomas Espeseth<sup>55,56</sup>, Xavier Estivill<sup>46-48,57</sup>,  
13 Anne Farmer<sup>19</sup>, Angela Favaro<sup>38</sup>, Fernando Fernández-Aranda<sup>58,59</sup>, Manfred M. Fichter<sup>60,61</sup>, Krista  
14 Fischer<sup>53</sup>, James A. B. Floyd<sup>62</sup>, Manuel Föcker<sup>63</sup>, Lenka Foretova<sup>64</sup>, Andreas J. Forstner<sup>27,65,66</sup>,  
15 Monica Forzan<sup>24</sup>, Christopher S. Franklin<sup>16</sup>, Steven Gallinger<sup>67</sup>, Giovanni Gambaro<sup>68</sup>, Hélène A.  
16 Gaspar<sup>19,20</sup>, Ina Giegling<sup>69</sup>, Paola Giusti-Rodríguez<sup>31</sup>, Fragiskos Gonidakis<sup>43</sup>, Scott Gordon<sup>70</sup>,  
17 Philip Gorwood<sup>50,51</sup>, Monica Gratacos Mayora<sup>46-48</sup>, Jakob Grove<sup>71-74</sup>, Sébastien Guillaume<sup>29</sup>, Yiran  
18 Guo<sup>75</sup>, Hakon Hakonarson<sup>75,76</sup>, Katherine A. Halmi<sup>77</sup>, Ken B. Hanscombe<sup>19</sup>, Konstantinos  
19 Hatzikotoulas<sup>16,78</sup>, Joanna Hauser<sup>79</sup>, Johannes Hebebrand<sup>80</sup>, Sietske G. Helder<sup>19,81</sup>, Anjali  
20 Henders<sup>82</sup>, Stefan Herms<sup>25,26</sup>, Beate Herpertz-Dahlmann<sup>83</sup>, Wolfgang Herzog<sup>84</sup>, Anke Hinney<sup>80</sup>, L.  
21 John Horwood<sup>14</sup>, Christopher Hübel<sup>19,85</sup>, Laura M. Huckins<sup>86-89</sup>, James I. Hudson<sup>90</sup>, Hartmut  
22 Imgart<sup>91</sup>, Hidetoshi Inoko<sup>92</sup>, Vladimir Janout<sup>93</sup>, Susana Jiménez-Murcia<sup>58,59</sup>, Craig Johnson<sup>94</sup>,  
23 Jessica S. Johnson<sup>86,87</sup>, Jennifer Jordan<sup>95,96</sup>, Antonio Julia<sup>97</sup>, Gursharan Kalsi<sup>19</sup>, Deborah  
24 Kaminská<sup>98</sup>, Allan S. Kaplan<sup>99-101</sup>, Jaakko Kaprio<sup>102</sup>, Leila Karhunen<sup>103</sup>, Andreas Karwautz<sup>104</sup>,  
25 Martien J. H. Kas<sup>1,105</sup>, Walter H. Kaye<sup>106</sup>, James L. Kennedy<sup>99-101</sup>, Martin A. Kennedy<sup>107</sup>, Anna  
26 Keski-Rahkonen<sup>108</sup>, Kirsty Kiezebrink<sup>109</sup>, Youl-Ri Kim<sup>110</sup>, Katherine M. Kirk<sup>111</sup>, Lars Klareskog<sup>112</sup>,  
27 Kelly L. Klump<sup>113</sup>, Gun Peggy S. Knudsen<sup>114</sup>, Maria C. La Via<sup>8</sup>, Mikael Landén<sup>13,115</sup>, Janne T.  
28 Larsen<sup>72,85,116</sup>, Stephanie Le Hellard<sup>117,118</sup>, Virpi M. Leppä<sup>13</sup>, Dong Li<sup>75</sup>, Paul Lichtenstein<sup>13</sup>, Lisa

29 Lilienfeld<sup>119</sup>, Bochao Danae Lin<sup>1</sup>, Jolanta Lissowska<sup>120</sup>, Astri J. Lundervold<sup>121</sup>, Jurjen Luykx<sup>1</sup>,  
30 Pierre J. Magistretti<sup>122-123</sup>, Mario Maj<sup>124</sup>, Katrin Mannik<sup>53,125</sup>, Sara Marsal<sup>97</sup>, Christian R.  
31 Marshall<sup>126</sup>, Nicholas G. Martin<sup>70</sup>, Manuel Mattheisen<sup>32,71,127,128</sup>, Morten Mattingsdal<sup>6</sup>, Sara  
32 McDevitt<sup>129,130</sup>, Peter McGuffin<sup>19</sup>, Sarah E. Medland<sup>111</sup>, Andres Metspalu<sup>53,131</sup>, Ingrid  
33 Meulenbelt<sup>132</sup>, Nadia Micali<sup>133,134</sup>, James Mitchell<sup>135</sup>, Karen Mitchell<sup>136,137</sup>, Alessio Maria  
34 Monteleone<sup>124</sup>, Palmiero Monteleone<sup>138</sup>, Grant W. Montgomery<sup>82,111,139</sup>, Preben Bo  
35 Mortensen<sup>72,85,116</sup>, Melissa A. Munn-Chernoff<sup>8</sup>, Benedetta Nacmias<sup>140,141</sup>, Marie Navratilova<sup>64</sup>,  
36 Ioanna Ntalla<sup>37</sup>, Catherine M. Olsen<sup>142</sup>, Roel A. Ophoff<sup>143,144</sup>, Julie O'Toole<sup>145</sup>, Leonid  
37 Padyukov<sup>112</sup>, Aarno Palotie<sup>54,102,146</sup>, Jacques Pantel<sup>147</sup>, Hana Papezova<sup>98</sup>, Richard Parker<sup>111</sup>, John  
38 F. Pearson<sup>148</sup>, Nancy L. Pedersen<sup>13</sup>, Triinu Peters<sup>80</sup>, Liselotte V. Petersen<sup>72,85,116</sup>, Dalila Pinto<sup>87</sup>,  
39 Kirstin L. Purves<sup>19</sup>, Anu Raevuori<sup>108,149</sup>, Nicolas Ramoz<sup>51</sup>, Ted Reichborn-Kjennerud<sup>114,150</sup>, Valdo  
40 Ricca<sup>151</sup>, Samuli Ripatti<sup>152</sup>, Stephan Ripke<sup>153-155</sup>, Marion Roberts<sup>19</sup>, Alessandro Rotondo<sup>156</sup>, Dan  
41 Rujescu<sup>69</sup>, Filip Rybakowski<sup>157</sup>, Paolo Santonastaso<sup>158</sup>, André Scherag<sup>159</sup>, Stephen W.  
42 Scherer<sup>160,161</sup>, Ulrike Schmidt<sup>162</sup>, Nicholas J. Schork<sup>163</sup>, Alexandra Schosser<sup>164</sup>, Jochen Seitz<sup>83</sup>,  
43 Lenka Slachtova<sup>165</sup>, P. Eline Slagboom<sup>132</sup>, Margarita C. T. Slof-Op't Landt<sup>166,167</sup>, Agnieszka  
44 Slopian<sup>168</sup>, Nicole Soranzo<sup>16,169-171</sup>, Sandro Sorbi<sup>140,141</sup>, Lorraine Southam<sup>16,78</sup>, Vidar W.  
45 Steen<sup>172,173</sup>, Michael Strober<sup>174,175</sup>, Garret D. Stuber<sup>8,176</sup>, Patrick F. Sullivan<sup>8,13,31</sup>, Beata  
46 Świątkowska<sup>177</sup>, Jin P. Szatkiewicz<sup>31</sup>, Ioanna Tachmazidou<sup>16</sup>, Friederike I. Tam<sup>15,178</sup>, Elena  
47 Tenconi<sup>38</sup>, Laura M. Thornton<sup>8</sup>, Alfonso Tortorella<sup>179</sup>, Federica Tozzi<sup>180</sup>, Janet Treasure<sup>19</sup>, Artemis  
48 Tsitsika<sup>181</sup>, Marta Tyszkiewicz-Nwafor<sup>168</sup>, Konstantinos Tziouvas<sup>182</sup>, Annemarie van Elburg<sup>2,183</sup>,  
49 Eric F. van Furth<sup>166,167</sup>, Tracey D. Wade<sup>184</sup>, Gudrun Wagner<sup>104</sup>, Esther Walton<sup>15</sup>, Hunna J.  
50 Watson<sup>8,185,186</sup>, Thomas Werge<sup>187</sup>, David C. Whiteman<sup>142</sup>, H-Erich Wichmann<sup>188</sup>, Elisabeth  
51 Widen<sup>102</sup>, D. Blake Woodside<sup>100,101,189,190</sup>, Jiayi Xu<sup>86</sup>, Shuyang Yao<sup>13</sup>, Zeynep Yilmaz<sup>8,13,31,85</sup>,  
52 Eleftheria Zeggini<sup>16,78,191</sup>, Stephanie Zerwas<sup>8</sup>, Stephan Zipfel<sup>192,193</sup>.

53

54

55

56 <sup>1</sup>Brain Center Rudolf Magnus, Department of Translational Neuroscience, University Medical Center Utrecht, Utrecht, The  
57 Netherlands.<sup>2</sup>Center for Eating Disorders Rintveld, Altrecht Mental Health Institute, Zeist, The Netherlands.<sup>3</sup>Sahlgrenska  
58 Academy, University of Gothenburg, Gothenburg, Sweden.<sup>4</sup>Institute of Environmental Medicine, Karolinska Institutet,  
59 Stockholm, Sweden. <sup>5</sup>Department of Behavioral Medicine, National Institute of Mental Health, National Center of  
60 Neurology and Psychiatry, Kodaira, Tokyo, Japan. <sup>6</sup>NORMENT KG Jebsen Centre, Division of Mental Health and  
61 Addiction, University of Oslo, Oslo University Hospital, Oslo, Norway.<sup>7</sup>Biopsychosocial Corporation, Vienna, Austria.  
62 <sup>8</sup>Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. <sup>9</sup>First Faculty of  
63 Medicine, Institute of Hygiene and Epidemiology, Charles University, Prague, Czech Republic. <sup>10</sup>BioRealm, LLC, Walnut,  
64 California, USA. <sup>11</sup>Oregon Research Institute, Eugene, Oregon, USA. <sup>12</sup>Department of Psychiatry, Center for Neurobiology  
65 and Behavior, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. <sup>13</sup>Department of  
66 Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. <sup>14</sup>Christchurch Health and Development  
67 Study, University of Otago, Christchurch, New Zealand. <sup>15</sup>Division of Psychological and Social Medicine and  
68 Developmental Neurosciences, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany. <sup>16</sup>Wellcome  
69 Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK. <sup>17</sup>Department of Medical Biology, School of  
70 Medicine, University of Split, Split, Croatia. <sup>18</sup>The Center for Eating Disorders at Sheppard Pratt, Baltimore, Maryland,  
71 USA. <sup>19</sup>Institute of Psychiatry, Psychology and Neuroscience, Social, Genetic and Developmental Psychiatry (SGDP)  
72 Centre, King's College London, London, UK. <sup>20</sup>National Institute for Health Research Biomedical Research Centre, King's  
73 College London and South London and Maudsley National Health Service Trust, London, UK. <sup>21</sup>Department of Nutrition,  
74 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. <sup>22</sup>Klinikum Frankfurt/Oder, Frankfurt,  
75 Germany. <sup>23</sup>Medical University of Vienna, Vienna, Austria. <sup>24</sup>Clinical Genetics Unit, Department of Woman and Child  
76 Health, University of Padova, Padova, Italy. <sup>25</sup>Institute of Medical Genetics and Pathology, University Hospital Basel,  
77 Basel, Switzerland. <sup>26</sup>Department of Biomedicine, University of Basel, Basel, Switzerland. <sup>27</sup>Institute of Neuroscience and  
78 Medicine (INM-1), Research Center Juelich, Juelich, Germany. <sup>28</sup>Life Sciences Institute and Department of Molecular and  
79 Integrative Physiology, University of Michigan, Ann Arbor, Michigan, USA. <sup>29</sup>Department of Emergency Psychiatry and  
80 Post-Acute Care, CHRU Montpellier, University of Montpellier, Montpellier, France. <sup>30</sup>Department of Psychiatry, University  
81 of Minnesota, Minneapolis, Minnesota, USA. <sup>31</sup>Department of Genetics, University of North Carolina at Chapel Hill, Chapel  
82 Hill, North Carolina, USA. <sup>32</sup>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. <sup>33</sup>MRC  
83 Integrative Epidemiology Unit, University of Bristol, Bristol, UK. <sup>34</sup>Bristol Medical School, University of Bristol, Bristol,  
84 UK. <sup>35</sup>The Alan Turing Institute, London, UK. <sup>36</sup>Department of Psychosomatic Medicine and Psychotherapy, Hannover  
85 Medical School, Hannover, Germany. <sup>37</sup>Department of Nutrition and Dietetics, Harokopio University, Athens,  
86 Greece. <sup>38</sup>Department of Neurosciences, University of Padova, Padova, Italy. <sup>39</sup>College of Nursing, Seattle University,  
87 Seattle, Washington, USA. <sup>40</sup>Department of Psychology, Virginia Commonwealth University, Richmond, Virginia,  
88 USA. <sup>41</sup>College Behavioral and Emotional Health Institute, Virginia Commonwealth University, Richmond, Virginia,  
89 USA. <sup>42</sup>Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, Virginia, USA. <sup>43</sup>First  
90 Department of Psychiatry, National and Kapodistrian University of Athens, Medical School, Eginition Hospital, Athens,

91 Greece.<sup>44</sup>L'institut du thorax, INSERM, CNRS, UNIV Nantes, Nantes, France.<sup>45</sup>Department of Psychiatric Genetics,  
92 Poznan University of Medical Sciences, Poznan, Poland.<sup>46</sup>Barcelona Institute of Science and Technology, Barcelona,  
93 Spain.<sup>47</sup>Universitat Pompeu Fabra, Barcelona, Spain.<sup>48</sup>Centro de Investigación Biomédica en Red en Epidemiología y  
94 Salud Pública (CIBERESP), Barcelona, Spain.<sup>49</sup>Department of Psychiatry and Behavioral Sciences, Stanford University,  
95 Stanford, California, USA.<sup>50</sup>GHU Paris Psychiatrie et Neurosciences, CMME, Paris Descartes University, Paris,  
96 France.<sup>51</sup>INSERM U1266, Institute of Psychiatry and Neurosciences, Paris, France.<sup>52</sup>Department of Child and Adolescent  
97 Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg, Centre for Mental Health, Würzburg,  
98 Germany.<sup>53</sup>Estonian Genome Center, University of Tartu, Tartu, Estonia.<sup>54</sup>Program in Medical and Population Genetics,  
99 Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts,  
100 USA.<sup>55</sup>Department of Psychology, University of Oslo, Oslo, Norway.<sup>56</sup>Bjørknes College, Oslo, Norway.<sup>57</sup>Genomics and  
101 Disease, Bioinformatics and Genomics Programme, Centre for Genomic Regulation, Barcelona, Spain.<sup>58</sup>Department of  
102 Psychiatry, University Hospital of Bellvitge – IDIBELL and CIBERObn, Barcelona, Spain.<sup>59</sup>Department of Clinical  
103 Sciences, School of Medicine, University of Barcelona, Barcelona, Spain.<sup>60</sup>Department of Psychiatry and Psychotherapy,  
104 Ludwig-Maximilians-University (LMU), Munich, Germany.<sup>61</sup>Schön Klinik Roseneck affiliated with the Medical Faculty of the  
105 University of Munich, Munich, Germany.<sup>62</sup>Genomics plc, Genomics PLC, Oxford, UK.<sup>63</sup>Department of Child and  
106 Adolescent Psychiatry, University of Münster, Münster, Germany.<sup>64</sup>Department of Cancer, Epidemiology and Genetics,  
107 Masaryk Memorial Cancer Institute, Brno, Czech Republic.<sup>65</sup>Institute of Human Genetics, University of Bonn, School of  
108 Medicine and University Hospital Bonn, Bonn, Germany.<sup>66</sup>Centre for Human Genetics, University of Marburg, Marburg,  
109 Germany.<sup>67</sup>Department of Surgery, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.<sup>68</sup>Division of  
110 Nephrology and Dialysis, Department of Medicine, AOVR, Ospedale Maggiore, Verona, Italy.<sup>69</sup>Department of Psychiatry,  
111 Psychotherapy and Psychosomatics, Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany.<sup>70</sup>Genetics and  
112 Computational Biology Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland,  
113 Australia.<sup>71</sup>Department of Biomedicine, Aarhus University, Aarhus, Denmark.<sup>72</sup>The Lundbeck Foundation Initiative for  
114 Integrative Psychiatric Research (iPSYCH), Aarhus, Denmark.<sup>73</sup>Centre for Integrative Sequencing, iSEQ, Aarhus  
115 University, Aarhus, Denmark.<sup>74</sup>Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark.<sup>75</sup>Center for Applied  
116 Genomics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.<sup>76</sup>Department of Pediatrics, University of  
117 Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.<sup>77</sup>Department of Psychiatry, Weill Cornell  
118 Medical College, New York, New York, USA.<sup>78</sup>Institute of Translational Genomics, Helmholtz Zentrum München – German  
119 Research Centre for Environmental Health, Neuherberg, Germany.<sup>79</sup>Department of Adult Psychiatry, Poznan University of  
120 Medical Sciences, Poznan, Poland.<sup>80</sup>Department of Child and Adolescent Psychiatry, University Hospital Essen,  
121 University of Duisburg-Essen, Essen, Germany.<sup>81</sup>Zorg op Orde, Delft, The Netherlands.<sup>82</sup>Institute for Molecular  
122 Bioscience, University of Queensland, Brisbane, Queensland, Australia.<sup>83</sup>Department of Child and Adolescent Psychiatry,  
123 Psychosomatics and Psychotherapy, RWTH Aachen University, Aachen, Germany.<sup>84</sup>Department of General Internal  
124 Medicine and Psychosomatics, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.<sup>85</sup>National  
125 Centre for Register-Based Research, Aarhus BSS, Aarhus University, Aarhus, Denmark.<sup>86</sup>Pamela Sklar Division of

126 Psychiatric Genomics, Icahn School of Medicine at Mount Sinai, New York, New York, USA.<sup>87</sup>Department of Psychiatry,  
127 and Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.<sup>88</sup>Seaver  
128 Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York, USA.<sup>89</sup>Mental  
129 Illness Research, Education and Clinical Centers, James J. Peters Department of Veterans Affairs Medical Center, Bronx,  
130 New York, USA.<sup>90</sup>Biological Psychiatry Laboratory, McLean Hospital/Harvard Medical School, Boston, Massachusetts,  
131 USA.<sup>91</sup>Eating Disorders Unit, Parklandklinik, Bad Wildungen, Germany.<sup>92</sup>Department of Molecular Life Science, Division  
132 of Basic Medical Science and Molecular Medicine, School of Medicine, Tokai University, Isehara, Japan.<sup>93</sup>Faculty of  
133 Health Sciences, Palacky University, Olomouc, Czech Republic.<sup>94</sup>Eating Recovery Center, Denver, Colorado,  
134 USA.<sup>95</sup>Department of Psychological Medicine, University of Otago, Christchurch, New Zealand.<sup>96</sup>Canterbury District  
135 Health Board, Christchurch, New Zealand.<sup>97</sup>Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona,  
136 Spain.<sup>98</sup>First Faculty of Medicine, Department of Psychiatry, Charles University, Prague, Czech Republic.<sup>99</sup>Centre for  
137 Addiction and Mental Health, Toronto, Ontario, Canada.<sup>100</sup>Institute of Medical Science, University of Toronto, Toronto,  
138 Ontario, Canada.<sup>101</sup>Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.<sup>102</sup>Institute for Molecular  
139 Medicine Finland FIMM, HiLIFE, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.<sup>103</sup>Institute of  
140 Public Health and Clinical Nutrition, Department of Clinical Nutrition, University of Eastern Finland, Kuopio,  
141 Finland.<sup>104</sup>Eating Disorders Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna,  
142 Austria.<sup>105</sup>Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, The  
143 Netherlands.<sup>106</sup>Department of Psychiatry, University of California San Diego, San Diego, California, USA.<sup>107</sup>Department of  
144 Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand.<sup>108</sup>Department of Public Health,  
145 University of Helsinki, Helsinki, Finland.<sup>109</sup>Institute of Applied Health Sciences, School of Medicine, Medical Sciences and  
146 Nutrition, University of Aberdeen, Aberdeen, UK.<sup>110</sup>Department of Psychiatry, Seoul Paik Hospital, Inje University, Seoul,  
147 Korea.<sup>111</sup>QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.<sup>112</sup>Division of Rheumatology,  
148 Department of Medicine, Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital,  
149 Stockholm, Sweden.<sup>113</sup>Department of Psychology, Michigan State University, East Lansing, Michigan, USA.<sup>114</sup>Department  
150 of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway.<sup>115</sup>Department of Psychiatry and Neurochemistry,  
151 Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg,  
152 Sweden.<sup>116</sup>Centre for Integrated Register-based Research (CIRRAU), Aarhus University, Aarhus, Denmark.<sup>117</sup>Dr. Einar  
153 Martens Research Group for Biological Psychiatry, Center for Medical Genetics and Molecular Medicine, Haukeland  
154 University Hospital, Bergen, Norway.<sup>118</sup>Department of Clinical Medicine, Laboratory Building, Haukeland University  
155 Hospital, Bergen, Norway.<sup>119</sup>The Chicago School of Professional Psychology, Washington D.C., USA.<sup>120</sup>Department of  
156 Cancer Epidemiology and Prevention, M. Sklodowska-Curie National Research Institute of Oncology, Warsaw,  
157 Poland.<sup>121</sup>Department of Biological and Medical Psychology, University of Bergen, Bergen, Norway.<sup>122</sup>BESE Division,  
158 KAUST, KSA, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia.<sup>123</sup>Department of Psychiatry,  
159 University of Lausanne-University Hospital of Lausanne (UNIL-CHUV), Lausanne, Switzerland.<sup>124</sup>Department of  
160 Psychiatry, University of Campania "Luigi Vanvitelli", Naples, Italy.<sup>125</sup>Center for Integrative Genomics, University of

161 Lausanne, Lausanne, Switzerland.<sup>126</sup>Department of Paediatric Laboratory Medicine, Division of Genome Diagnostics, The  
162 Hospital for Sick Children, Toronto, Ontario, Canada.<sup>127</sup>Center for Psychiatry Research, Stockholm Health Care Services,  
163 Stockholm City Council, Stockholm, Sweden.<sup>128</sup>Department of Psychiatry, Psychosomatics and Psychotherapy, University  
164 of Würzburg, Würzburg, Germany.<sup>129</sup>Department of Psychiatry, University College Cork, Cork, Ireland.<sup>130</sup>Child and  
165 Adolescent Regional Eating Disorder Service (CAREDS), Health Service Executive South, Cork, Ireland.<sup>131</sup>Institute of  
166 Molecular and Cell Biology, University of Tartu, Tartu, Estonia.<sup>132</sup>Molecular Epidemiology Section, Department of  
167 Biomedical Datasciences, Leiden University Medical Centre, Leiden, The Netherlands.<sup>133</sup>Department of Psychiatry,  
168 Faculty of Medicine, University of Geneva, Geneva, Switzerland.<sup>134</sup>Department of Pediatrics, Gynaecology and Obstetrics,  
169 University of Geneva, Geneva, Switzerland.<sup>135</sup>Department of Psychiatry and Behavioral Science, University of North  
170 Dakota School of Medicine and Health Sciences, Fargo, North Dakota, USA.<sup>136</sup>National Center for PTSD, VA Boston  
171 Healthcare System, Boston, Massachusetts, USA.<sup>137</sup>Department of Psychiatry, Boston University School of Medicine,  
172 Boston, Massachusetts, USA.<sup>138</sup>Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University  
173 of Salerno, Salerno, Italy.<sup>139</sup>Queensland Brain Institute, University of Queensland, Brisbane, Queensland,  
174 Australia.<sup>140</sup>Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), University of  
175 Florence, Florence, Italy.<sup>141</sup>IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.<sup>142</sup>Population Health Department,  
176 QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.<sup>143</sup>Center for Neurobehavioral Genetics,  
177 Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California,  
178 USA.<sup>144</sup>Department of Psychiatry, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The  
179 Netherlands.<sup>145</sup>Kartini Clinic, Portland, Oregon, USA.<sup>146</sup>Center for Human Genome Research, Massachusetts General  
180 Hospital, Boston, Massachusetts, USA.<sup>147</sup>INSERM U1124, Université de Paris, Paris, France.<sup>148</sup>Biostatistics and  
181 Computational Biology Unit, University of Otago, Christchurch, New Zealand.<sup>149</sup>Department of Adolescent Psychiatry,  
182 Helsinki University Hospital, Helsinki, Finland.<sup>150</sup>Institute of Clinical Medicine, University of Oslo, Oslo,  
183 Norway.<sup>151</sup>Department of Health Science, University of Florence, Florence, Italy.<sup>152</sup>Department of Biometry, University of  
184 Helsinki, Helsinki, Finland.<sup>153</sup>Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General  
185 Hospital and Harvard Medical School, Boston, Massachusetts, USA.<sup>154</sup>Stanley Center for Psychiatric Research, Broad  
186 Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts,  
187 USA.<sup>155</sup>Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin, Berlin, Germany.<sup>156</sup>Department of  
188 Psychiatry, Neurobiology, Pharmacology, and Biotechnologies, University of Pisa, Pisa, Italy.<sup>157</sup>Department of Psychiatry,  
189 Poznan University of Medical Sciences, Poznan, Poland.<sup>158</sup>Department of Neurosciences, Padua Neuroscience Center,  
190 University of Padova, Padova, Italy.<sup>159</sup>Institute of Medical Statistics, Computer and Data Sciences, Jena University  
191 Hospital, Jena, Germany.<sup>160</sup>Department of Genetics and Genomic Biology, The Hospital for Sick Children, Toronto,  
192 Ontario, Canada.<sup>161</sup>McLaughlin Centre, University of Toronto, Toronto, Ontario, Canada.<sup>162</sup>Institute of Psychiatry,  
193 Psychology and Neuroscience, Psychological Medicine, King’s College London, London, UK.<sup>163</sup>J. Craig Venter Institute  
194 (JCVI), La Jolla, California, USA.<sup>164</sup>Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna,  
195 Austria.<sup>165</sup>First Faculty of Medicine, Department of Biology and Medical Genetics, Charles University, Prague, Czech

196 Republic.<sup>166</sup>Center for Eating Disorders Ursula, Rivierduinen, Leiden, The Netherlands.<sup>167</sup>Department of Psychiatry,  
197 Leiden University Medical Centre, Leiden, The Netherlands.<sup>168</sup>Department of Child and Adolescent Psychiatry, Poznan  
198 University of Medical Sciences, Poznan, Poland.<sup>169</sup>Donor Health and Genomics, National Institute for Health Research  
199 Blood and Transplant Unit, Cambridge, UK.<sup>170</sup>Division of Cardiovascular Medicine, British Heart Foundation Centre of  
200 Excellence, Cambridge, UK.<sup>171</sup>Department of Haematology, University of Cambridge, Cambridge, UK.<sup>172</sup>Center for  
201 Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway.<sup>173</sup>Department of Clinical  
202 Science, University of Bergen, Bergen, Norway.<sup>174</sup>Department of Psychiatry and Biobehavioral Science, Semel Institute  
203 for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California, USA.<sup>175</sup>David  
204 Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.<sup>176</sup>Department of Cell  
205 Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.<sup>177</sup>Department of  
206 Environmental Epidemiology, Nofer Institute of Occupational Medicine, Lodz, Poland.<sup>178</sup>Eating Disorders Research and  
207 Treatment Center, Department of Child and Adolescent Psychiatry, Faculty of Medicine, Technische Universität Dresden,  
208 Dresden, Germany.<sup>179</sup>Department of Psychiatry, University of Perugia, Perugia, Italy.<sup>180</sup>Brain Sciences Department,  
209 Stremble Ventures, Limassol, Cyprus.<sup>181</sup>Adolescent Health Unit, Second Department of Pediatrics, "P. & A. Kyriakou"  
210 Children's Hospital, University of Athens, Athens, Greece.<sup>182</sup>Pediatric Intensive Care Unit, "P. & A. Kyriakou" Children's  
211 Hospital, University of Athens, Athens, Greece.<sup>183</sup>Faculty of Social and Behavioral Sciences, Utrecht University, Utrecht,  
212 The Netherlands.<sup>184</sup>School of Psychology, Flinders University, Adelaide, South Australia, Australia.<sup>185</sup>School of  
213 Psychology, Curtin University, Perth, Western Australia, Australia.<sup>186</sup>School of Paediatrics and Child Health, University of  
214 Western Australia, Perth, Western Australia, Australia.<sup>187</sup>Department of Clinical Medicine, University of Copenhagen,  
215 Copenhagen, Denmark.<sup>188</sup>Helmholtz Centre Munich – German Research Center for Environmental Health, Munich,  
216 Germany.<sup>189</sup>Centre for Mental Health, University Health Network, Toronto, Ontario, Canada.<sup>190</sup>Program for Eating  
217 Disorders, University Health Network, Toronto, Ontario, Canada.<sup>191</sup>TUM School of Medicine, Technical University of  
218 Munich and Klinikum Rechts der Isar, Munich, Germany.<sup>192</sup>Department of Internal Medicine VI, Psychosomatic Medicine  
219 and Psychotherapy, University Medical Hospital Tuebingen, Tuebingen, Germany.<sup>193</sup>Centre of Excellence for Eating  
220 Disorders (KOMET), University Tuebingen, Tuebingen, Germany.  
221